Gut Bacteria Drive Age-Related Anemia Through a Hidden Epigenetic Switch
A gut microbe ramps up a metabolite that blocks red blood cell production — and restricting one amino acid may reverse it.
Summary
Anemia becomes increasingly common with age, raising risks for heart disease, cognitive decline, and death. New research pinpoints a surprising culprit: a gut bacterium called Odoribacter splanchnicus, which multiplies with age and produces phenylacetic acid (PAA) from the amino acid phenylalanine. PAA travels to the bone marrow and triggers an unusual chemical tag on histones — the proteins that package DNA — disrupting the genetic program needed for red blood cell development. Blocking this bacterium with rifaximin, inhibiting the enzyme responsible for the histone tag, or simply restricting dietary phenylalanine all reversed aging-related anemia in mice. The findings reveal a novel gut-microbiota-to-bone-marrow signaling axis and suggest several practical strategies for treating a condition that currently lacks targeted therapies.
Detailed Summary
Anemia affects a large share of older adults and is linked to accelerated cognitive decline, cardiovascular events, and increased mortality. Despite its prevalence, the biological mechanisms behind aging-related anemia — particularly at the epigenetic level in blood stem cells — have remained poorly understood. This study, published in Blood, offers a striking new explanation rooted in the gut microbiome.
Researchers found that aging activates phenylalanine metabolism in both humans and mice, raising circulating levels of phenylacetic acid (PAA). They identified Odoribacter splanchnicus, a gut bacterium that expands significantly with age, as the key driver of PAA production. This microbe converts phenylalanine to PAA via a specific enzymatic pathway encoded by genes porA, nifJ, and iorA/iorB. Treating aged mice with rifaximin selectively reduced this bacterium and lowered PAA, alleviating anemia.
Mechanistically, PAA promotes a newly described histone modification called lysine phenylacetylation (Kpa), mediated by the acetyltransferase HBO1. This epigenetic tag opens chromatin at the GATA2 promoter, disrupting the so-called GATA switch — a critical regulatory checkpoint in erythroid (red blood cell) differentiation. When this switch is blocked, hematopoietic stem and progenitor cells cannot properly mature into red blood cells.
The team validated these findings with multiple interventions: supplementing PAA worsened anemia in microbiota-depleted mice; an HBO1 inhibitor (WM-3835) restored normal red blood cell production; and dietary phenylalanine restriction lowered PAA and corrected anemia in both naturally aged and O. splanchnicus-colonized mice.
These findings establish a clear mechanistic chain from gut microbiota composition to epigenetic dysregulation in bone marrow, with multiple intervention points. Caveats include reliance on mouse models and abstract-only availability; human clinical validation is needed before any dietary or pharmacological strategies can be recommended.
Key Findings
- Odoribacter splanchnicus expands with age and produces phenylacetic acid (PAA), driving anemia via bone marrow epigenetic changes.
- PAA induces a novel histone modification (Kpa) via HBO1, blocking the GATA switch required for red blood cell maturation.
- Rifaximin selectively reduced O. splanchnicus and PAA levels, alleviating aging-related anemia in mice.
- Restricting dietary phenylalanine lowered circulating PAA and reversed anemia in aged and colonized mice.
- The HBO1 inhibitor WM-3835 restored normal erythropoiesis by reversing the pathological histone modification.
Methodology
The study used aged mice and human subjects to measure phenylalanine metabolism and PAA levels, germ-free and microbiota-depleted mouse models, and bacterial colonization experiments with O. splanchnicus. Mechanistic work involved epigenomic profiling, chromatin accessibility assays, and pharmacological interventions including rifaximin, sodium phenylacetate, the HBO1 inhibitor WM-3835, and phenylalanine-restricted diets.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. The majority of mechanistic evidence comes from mouse models, and human clinical validation of these interventions has not yet been reported. Dietary phenylalanine restriction in older adults requires careful monitoring given its essential amino acid status.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: